CLINICAL TRIALS PROFILE FOR TECHNETIUM TC-99M MEDRONATE KIT
✉ Email this page to a colleague
All Clinical Trials for TECHNETIUM TC-99M MEDRONATE KIT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03002454 ↗ | Sodium Pertechnetate (99Tc) Injection Generator: 99mTc From Neutron-activation 99Mo v 99mTc From Fission 99Mo | Terminated | Winnipeg Regional Health Authority | Phase 3 | 2016-08-01 | A non-fission sourced, solvent generator produced 99mTc intravenous injection, as 99mTc -MDP, is to be used as a bone scan diagnostic radiopharmaceutical for assessment of bone pathology using the same oncologic indications as nuclear reactor sourced 99mTc, as 99mTc-MDP. |
| NCT03002454 ↗ | Sodium Pertechnetate (99Tc) Injection Generator: 99mTc From Neutron-activation 99Mo v 99mTc From Fission 99Mo | Terminated | University of Manitoba | Phase 3 | 2016-08-01 | A non-fission sourced, solvent generator produced 99mTc intravenous injection, as 99mTc -MDP, is to be used as a bone scan diagnostic radiopharmaceutical for assessment of bone pathology using the same oncologic indications as nuclear reactor sourced 99mTc, as 99mTc-MDP. |
| NCT03707184 ↗ | Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone | Recruiting | University of Utah | Phase 2 | 2018-10-02 | This trial studies how well fluciclovine 18F PET/CT imaging works in assessing hormone-naive men with prostate cancer that has spread to the bone. Fluciclovine 18F is a radioactive drug used to measure tumor growth. PET/CT uses x-rays to take pictures inside the body. Comparing results of fluciclovine 18F PET/CT imaging may help doctors predict a patient's response to treatment and help plan the best treatment. |
| NCT05924672 ↗ | Efficacy of Ra-223 in PSMA PET Optimally Selected Patients | RECRUITING | Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma | PHASE2 | 2024-08-30 | This phase II trial studies how well prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans (in combination with bone scans) work in selecting patients for Ra-223 radiation therapy that have castration-resistant prostate cancer that has spread from where it first started (primary site) to the bones (bone metastasis). Ra-223 is a type of therapy that emits radiation. Radiation gives off energy which can kill tumor cells and other cells that may support the tumor cells. Ra-223 is given by infusion into the veins, where it is absorbed by the bones. PSMA PET is a type of scan used to detect prostate cancer tumors. PSMA is a radioactive tracer that binds to a specific protein that is found on prostate tumor cells. The PSMA tracer shows the areas on the PET scan where tumor cells are active. A PET scan uses a special camera to detect the energy given off from radioactive tracers (such as PSMA) to make detailed pictures of areas where the tracer accumulates in the body. The PET scan is often combined with a magnetic resonance imaging (MRI) or computed tomography (CT) scan, which helps to map the locations where PSMA has accumulated. PSMA PET scans may be able to select patients that will benefit the most from Ra-223 treatment. |
| NCT05924672 ↗ | Efficacy of Ra-223 in PSMA PET Optimally Selected Patients | RECRUITING | University of California, San Francisco | PHASE2 | 2024-08-30 | This phase II trial studies how well prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans (in combination with bone scans) work in selecting patients for Ra-223 radiation therapy that have castration-resistant prostate cancer that has spread from where it first started (primary site) to the bones (bone metastasis). Ra-223 is a type of therapy that emits radiation. Radiation gives off energy which can kill tumor cells and other cells that may support the tumor cells. Ra-223 is given by infusion into the veins, where it is absorbed by the bones. PSMA PET is a type of scan used to detect prostate cancer tumors. PSMA is a radioactive tracer that binds to a specific protein that is found on prostate tumor cells. The PSMA tracer shows the areas on the PET scan where tumor cells are active. A PET scan uses a special camera to detect the energy given off from radioactive tracers (such as PSMA) to make detailed pictures of areas where the tracer accumulates in the body. The PET scan is often combined with a magnetic resonance imaging (MRI) or computed tomography (CT) scan, which helps to map the locations where PSMA has accumulated. PSMA PET scans may be able to select patients that will benefit the most from Ra-223 treatment. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TECHNETIUM TC-99M MEDRONATE KIT
Condition Name
| Condition Name for TECHNETIUM TC-99M MEDRONATE KIT | |
| Intervention | Trials |
| Cancer of Bone | 1 |
| Castration-Resistant Prostate Carcinoma | 1 |
| Metastatic Malignant Neoplasm in the Bone | 1 |
| Metastatic Prostate Carcinoma | 1 |
| [disabled in preview] | 1 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for TECHNETIUM TC-99M MEDRONATE KIT
Trials by Country
Clinical Trial Progress for TECHNETIUM TC-99M MEDRONATE KIT
Clinical Trial Phase
Clinical Trial Sponsors for TECHNETIUM TC-99M MEDRONATE KIT
Sponsor Name
